Reading Time: 2 minutes

Rite Aid to Pilot COVID-19 Testing at Philadelphia Location

CAMP HILL, Pa.–(BUSINESS WIRE)–Today, Rite Aid (NYSE: RAD) announced it has joined the White House COVID-19 Response Working Group. Rite Aid’s mission is to keep the communities it serves healthy and beginning Monday, March 23, the company is piloting COVID-19 testing at one location in Philadelphia seven days a week from 9 a.m. to 5 p.m.

Based on guidance from the Department of Health and Human Services, the only people who can be tested at this site are:

  • First Responders, Healthcare Workers* (regardless of presence of symptoms). *This includes only staff with direct contact with patients (not those in administrative roles) or as determined at the state level.

    • Definition of First Responder: Any individual responding to the public health task or mission, as determined by the jurisdiction.
    • Definition of Healthcare Worker: Any individual working or providing direct patient care in acute or critical settings (hospitals, clinics, long-term care facilities, emergency medicine).

Testing will occur in one Rite Aid store parking lot at 7401 Ogontz Ave., Philadelphia, PA 19138. As part of the testing process, people must remain in their vehicles from the time they arrive and until they depart.

Please note, media will not be provided access to the secure testing site or Rite Aid store.

Rite Aid will provide updates as the pilot progresses.

About Rite Aid Corporation

Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to more than 1.6 million Americans daily. Our pharmacists are uniquely positioned to engage with customers and improve their health outcomes. We provide an array of whole being health products and services for the entire family through over 2,400 retail pharmacy locations across 18 states. Through EnvisionRxOptions, we provide pharmacy benefits and services to approximately 4 million members nationwide. For more information, www.RiteAid.com.

Contacts

Media:

Chris Savarese

717-975-5718

[email protected]